Cottrill’s Specialty Pharmacy gets ACHC, URAC accreditations
Cottrill’s Specialty Pharmacy, an independent pharmacy based in Orchard, N.Y., recently received specialty pharmacy accreditations from the Accreditation Commission for Healthcare and URAC, as well as ACHC accreditation for home/durable medical equipment services.
In order to receive these accreditations, Cottrill’s Specialty Pharmacy, which is licensed in 47 states and has been around since 1899, had to show compliance with national standards of performance and patient care.
“Our team consists of experts in the fields of pharmacy, nursing, data Collection, compliance and patient advocacy,” David Obrochta, owner and president of Cottrill’s, said. “This allows us to maximize each patient’s treatment plan in the most effective and cost-efficient manner possible. We understand that every patient is unique, and that their needs may change, so we truly offer personalized care for every patient. Our goal is to exceed the expectations of our patients, providers, manufacturers and payers. Achieving accreditation with URAC and ACHC are two more ways that we demonstrate this commitment to providing the highest standards in patient care.”
Cottrill’s said it specializes in treating patients with chronic conditions, rare diseases and genetic disorders.
“The development of new, complex, and costly drugs makes good patient management an imperative,” URA president and CEO Kylanne Green said. “This makes accrediting pharmacies that manage patients more important than ever. We applaud Cottrill’s Pharmacy on achieving an accreditation of the quality of their pharmacy services through URAC. Cottrill’s shows a dedication to patient education and safety through the recognition of quality it received with URAC’s independent accreditation.”
Amneal’s erythromycin tablets launch
Amneal on Tuesday received Food and Drug Administration approval for its erythromycin tablets, immediately launching the product. Amneal said that its generic is the only alternative oral release tablet on the market.
“Amneal is committed to increasing access to affordable medications,” Amneal executive vice president of commercial operations Andy Boyer said. “Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options.”
Amneal’s tablets are sold in 100-count bottles of 25- and 50-mg dosage strength tablets.
The product had a market size of roughly $84 million in the 12 months ended January 2018, according to IQVIA data.
Lupin intros Tydemi, its Safyral generic
Lupin has launched its contraceptive Tydemy, which was approved by the Food and Drug Administration in December as a generic of Bayer’s Safyral. Tydemy, (drospirenone, ethinyl estradiol, and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg) are indicated to preven pregnancy and raise folate levels in women who prefer an oral contraceptive.
The drug had U.S. sales of roughly $22 million for the 12 months ended January 2018.